Soybean Bowman-Birk inhibitor conjugates with clinical dextran. Synthesis and antiproteolytic activity

I. P. Gladysheva, N. A. Moroz, A. I. Papisova, N. I. Larionova

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Conjugates of the classical soybean Bowman-Birk inhibitor (BBI) with clinical dextran were synthesized. Clinical dextran was preliminarily oxidized with periodate to dialdehydedextran (DAD). The effect of the degree of oxidation of DAD on coupling of the inhibitor was evaluated. The binding of the protein was shown to increase with increasing degree of DAD oxidation (5, 10, 20%). Total coupling of the inhibitor occurred when the degree of oxidation of the dextran was 20%. The BBI-DAD (20%) coniugate contained 13% protein with BBI/DAD molar ratio 1 : 1. The conjugates retained the ability to inhibit trypsin (Ki = 0.2-0.3 nM) and α-chymotrypsin (Ki = 15-30 nM). Thus, the coupling of BBI with the polymeric carrier caused practically no decrease in the antiproteolytic activity of the inhibitor.

Original languageEnglish (US)
Pages (from-to)384-389
Number of pages6
JournalBiochemistry (Moscow)
Volume66
Issue number4
DOIs
StatePublished - Apr 2001
Externally publishedYes

Keywords

  • Bowman-Birk inhibitor
  • Conjugate
  • Dextran

ASJC Scopus subject areas

  • Biochemistry

Fingerprint

Dive into the research topics of 'Soybean Bowman-Birk inhibitor conjugates with clinical dextran. Synthesis and antiproteolytic activity'. Together they form a unique fingerprint.

Cite this